Multiple Sclerosis and Related Disorders, 72:104561. Elsevier Ryerson, L Z, Foley, J F, Defer, G, Cohen, J A, Arnold, D L, Butzkueven, H, Cutter, G, Giovannoni, G, Killestein, J, Wiendl, H, Sinks, S, Kuhelj, R, Bodhinathan, K & Lasky, T 2023, ' Exploratory clinical efficacy and patient-reported outcomes from NOVA : A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting multiple sclerosis ', Multiple Sclerosis and Related Disorders, vol. 72, 104561 . https://doi.org/10.1016/j.msard.2023.104561
Foley, J F, Defer, G, Ryerson, L Z, Cohen, J A, Arnold, D L, Butzkueven, H, Cutter, G, Giovannoni, G, Killestein, J, Wiendl, H, Smirnakis, K, Xiao, S, Kong, G, NOVA study investigators, Kuhelj, R & Campbell, N 2022, ' Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA) : a randomised, controlled, open-label, phase 3b trial ', Lancet Neurology, vol. 21, no. 7, pp. 608-619 . https://doi.org/10.1016/S1474-4422(22)00143-0 The lancet neurology Lancet Neurology, 21(7), 608-619. Lancet Publishing Group